Novel cuproptosis-related lncRNAs risk model to predicting prognosis and guiding immunotherapy for OSCC patients

Abstract Background A significant role in many cancers is played by cuproptosis, a new term for the copper-dependent regulatory cell death pattern. However, as a new research hotspot, the cuproptosis-related lncRNAs (CRLs) associated with regulation in oral squamous cell carcinoma (OSCC) patients ar...

Full description

Saved in:
Bibliographic Details
Main Authors: Lingbo Kong, Chenfei Wang, Xiaohui Lu, Qianqi Zhu, Yihua Song, Xingmei Feng
Format: Article
Language:English
Published: Springer 2025-05-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-02578-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850154780929818624
author Lingbo Kong
Chenfei Wang
Xiaohui Lu
Qianqi Zhu
Yihua Song
Xingmei Feng
author_facet Lingbo Kong
Chenfei Wang
Xiaohui Lu
Qianqi Zhu
Yihua Song
Xingmei Feng
author_sort Lingbo Kong
collection DOAJ
description Abstract Background A significant role in many cancers is played by cuproptosis, a new term for the copper-dependent regulatory cell death pattern. However, as a new research hotspot, the cuproptosis-related lncRNAs (CRLs) associated with regulation in oral squamous cell carcinoma (OSCC) patients are currently not well understood. Methods Long noncoding RNA (lncRNA) data were downloaded from the Cancer Genome Atlas database (TCGA). The ‘LIMMA’ package in R software was used to screen for differential expression of CRLs. LASSO regression and COX regression models were used to construct prognostic signature based on 4 prognostic CRLs. Finally, the relationship of risk characteristics with immune correlation analysis, somatic mutations, PCA, biological molecular pathways and drug sensitivity was investigated. Results A cuproptosis-related lncRNAs prognostic signature was developed by us. Based on the risk scores, the OSCC samples were split into high- and low-risk groups using this signature. The two risk groups differed significantly in immune functions, drug sensitivity, and overall survival. The risk model showed better prognostic predictive power compared to the traditional clinicopathological signature. By qPCR trial, we also verified the expression of STARD4-AS1 in OSCC cell lines and tissues was in line with our results from this experimental screen. Through cell experiments, we have confirmed that knocking down STARD4-AS1 promotes the proliferation and migration ability of OSCC cells. Conclusion The CRLs signature contributes to new understandings of the treatment of OSCC and is a rubost biomarker for predicting the prognosis of patients with OSCC.
format Article
id doaj-art-d40e09517f0f465a90b4effdbf5dfd6d
institution OA Journals
issn 2730-6011
language English
publishDate 2025-05-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-d40e09517f0f465a90b4effdbf5dfd6d2025-08-20T02:25:12ZengSpringerDiscover Oncology2730-60112025-05-0116111410.1007/s12672-025-02578-0Novel cuproptosis-related lncRNAs risk model to predicting prognosis and guiding immunotherapy for OSCC patientsLingbo Kong0Chenfei Wang1Xiaohui Lu2Qianqi Zhu3Yihua Song4Xingmei Feng5Wuxi Stomatological HospitalDepartment of Stomatology, Affiliated Hospital of Nantong University, Medical School of Nantong UniversityDepartment of Stomatology, Affiliated Hospital of Nantong University, Medical School of Nantong UniversityDepartment of Stomatology, Affiliated Hospital of Nantong University, Medical School of Nantong UniversityDepartment of Stomatology, Affiliated Hospital of Nantong University, Medical School of Nantong UniversityDepartment of Stomatology, Affiliated Hospital of Nantong University, Medical School of Nantong UniversityAbstract Background A significant role in many cancers is played by cuproptosis, a new term for the copper-dependent regulatory cell death pattern. However, as a new research hotspot, the cuproptosis-related lncRNAs (CRLs) associated with regulation in oral squamous cell carcinoma (OSCC) patients are currently not well understood. Methods Long noncoding RNA (lncRNA) data were downloaded from the Cancer Genome Atlas database (TCGA). The ‘LIMMA’ package in R software was used to screen for differential expression of CRLs. LASSO regression and COX regression models were used to construct prognostic signature based on 4 prognostic CRLs. Finally, the relationship of risk characteristics with immune correlation analysis, somatic mutations, PCA, biological molecular pathways and drug sensitivity was investigated. Results A cuproptosis-related lncRNAs prognostic signature was developed by us. Based on the risk scores, the OSCC samples were split into high- and low-risk groups using this signature. The two risk groups differed significantly in immune functions, drug sensitivity, and overall survival. The risk model showed better prognostic predictive power compared to the traditional clinicopathological signature. By qPCR trial, we also verified the expression of STARD4-AS1 in OSCC cell lines and tissues was in line with our results from this experimental screen. Through cell experiments, we have confirmed that knocking down STARD4-AS1 promotes the proliferation and migration ability of OSCC cells. Conclusion The CRLs signature contributes to new understandings of the treatment of OSCC and is a rubost biomarker for predicting the prognosis of patients with OSCC.https://doi.org/10.1007/s12672-025-02578-0lncRNAsCuproptosisOral squamous cell carcinomaPrognostic signatureImmune microenvironmentImmune checkpoint
spellingShingle Lingbo Kong
Chenfei Wang
Xiaohui Lu
Qianqi Zhu
Yihua Song
Xingmei Feng
Novel cuproptosis-related lncRNAs risk model to predicting prognosis and guiding immunotherapy for OSCC patients
Discover Oncology
lncRNAs
Cuproptosis
Oral squamous cell carcinoma
Prognostic signature
Immune microenvironment
Immune checkpoint
title Novel cuproptosis-related lncRNAs risk model to predicting prognosis and guiding immunotherapy for OSCC patients
title_full Novel cuproptosis-related lncRNAs risk model to predicting prognosis and guiding immunotherapy for OSCC patients
title_fullStr Novel cuproptosis-related lncRNAs risk model to predicting prognosis and guiding immunotherapy for OSCC patients
title_full_unstemmed Novel cuproptosis-related lncRNAs risk model to predicting prognosis and guiding immunotherapy for OSCC patients
title_short Novel cuproptosis-related lncRNAs risk model to predicting prognosis and guiding immunotherapy for OSCC patients
title_sort novel cuproptosis related lncrnas risk model to predicting prognosis and guiding immunotherapy for oscc patients
topic lncRNAs
Cuproptosis
Oral squamous cell carcinoma
Prognostic signature
Immune microenvironment
Immune checkpoint
url https://doi.org/10.1007/s12672-025-02578-0
work_keys_str_mv AT lingbokong novelcuproptosisrelatedlncrnasriskmodeltopredictingprognosisandguidingimmunotherapyforosccpatients
AT chenfeiwang novelcuproptosisrelatedlncrnasriskmodeltopredictingprognosisandguidingimmunotherapyforosccpatients
AT xiaohuilu novelcuproptosisrelatedlncrnasriskmodeltopredictingprognosisandguidingimmunotherapyforosccpatients
AT qianqizhu novelcuproptosisrelatedlncrnasriskmodeltopredictingprognosisandguidingimmunotherapyforosccpatients
AT yihuasong novelcuproptosisrelatedlncrnasriskmodeltopredictingprognosisandguidingimmunotherapyforosccpatients
AT xingmeifeng novelcuproptosisrelatedlncrnasriskmodeltopredictingprognosisandguidingimmunotherapyforosccpatients